JAZZ PHARMACEUTICALS PLC

(JAZZ)
  Report
Real-time Estimate Cboe BZX  -  05/25 01:12:36 pm EDT
146.42 USD   +2.41%
01:27aEmyria Validates Safety of Cannabidiol Product from Phase 1 Study; Shares Sink 8%
MT
05/11INSIDER SELL : Jazz Pharmaceuticals
MT
05/10TRANSCRIPT : Jazz Pharmaceuticals plc Presents at Bank of America 2022 Healthcare Conference, May-10-2022 12:40 PM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Jazz Pharmaceuticals : GW Pharmaceuticals Bags UK Nod for New Use of Cannabis-Based Seizure Drug

08/10/2021 | 10:25am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
AURORA CANNABIS INC. 1.22% 3.31 Delayed Quote.-52.26%
AUXLY CANNABIS GROUP INC. 0.00% 0.125 Delayed Quote.-32.43%
CANOPY GROWTH CORPORATION 3.47% 6.27 Delayed Quote.-45.11%
CRONOS GROUP INC. 0.52% 3.88 Delayed Quote.-22.49%
HEXO CORP. 1.56% 0.325 Delayed Quote.-63.64%
JAZZ PHARMACEUTICALS PLC 2.04% 145.965 Delayed Quote.12.23%
ORGANIGRAM HOLDINGS INC. 0.69% 1.45 Delayed Quote.-35.14%
THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD. -5.00% 0.095 Delayed Quote.5.26%
All news about JAZZ PHARMACEUTICALS PLC
01:27aEmyria Validates Safety of Cannabidiol Product from Phase 1 Study; Shares Sink 8%
MT
05/11INSIDER SELL : Jazz Pharmaceuticals
MT
05/10TRANSCRIPT : Jazz Pharmaceuticals plc Presents at Bank of America 2022 Healthcare Conferen..
CI
05/10Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi (solriamfetol) to Axsome Ther..
AQ
05/09Jazz Pharmaceuticals Completes Sale Of Sleep Treatment Product For $53 Million
MT
05/09Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive ..
PR
05/05Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Fin..
AQ
05/05RBC Capital Adjusts Jazz Pharmaceuticals' Price Target to $208 From $210, Maintains Out..
MT
05/05Piper Sandler Adjusts Jazz Pharmaceuticals' Price Target to $193 From $197, Reiterates ..
MT
05/05INSIDER SELL : Jazz Pharmaceuticals
MT
More news
Analyst Recommendations on JAZZ PHARMACEUTICALS PLC
More recommendations
Financials (USD)
Sales 2022 3 597 M - -
Net income 2022 381 M - -
Net Debt 2022 4 749 M - -
P/E ratio 2022 14,7x
Yield 2022 -
Capitalization 8 910 M 8 910 M -
EV / Sales 2022 3,80x
EV / Sales 2023 3,37x
Nbr of Employees 3 200
Free-Float 97,4%
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 142,98 $
Average target price 199,95 $
Spread / Average Target 39,8%
EPS Revisions
Managers and Directors
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher President
Renée D. Galá Chief Financial Officer & Executive Vice President
Robert Iannone Chief Medical Officer, EVP-Research & Development
Finbar Larkin Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
JAZZ PHARMACEUTICALS PLC12.23%8 910
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494